4-(2-amino-4-oxo-7-(4-pentylphenyl)-3-((5-phenyltetrahydrofuran-2-yl)methyl)-3,4-dihydroquinazolin-5-yl)benzoic acid

ID: ALA5194332

Chembl Id: CHEMBL5194332

PubChem CID: 168290161

Max Phase: Preclinical

Molecular Formula: C37H37N3O4

Molecular Weight: 587.72

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCCc1ccc(-c2cc(-c3ccc(C(=O)O)cc3)c3c(=O)n(CC4CCC(c5ccccc5)O4)c(N)nc3c2)cc1

Standard InChI:  InChI=1S/C37H37N3O4/c1-2-3-5-8-24-11-13-25(14-12-24)29-21-31(26-15-17-28(18-16-26)36(42)43)34-32(22-29)39-37(38)40(35(34)41)23-30-19-20-33(44-30)27-9-6-4-7-10-27/h4,6-7,9-18,21-22,30,33H,2-3,5,8,19-20,23H2,1H3,(H2,38,39)(H,42,43)

Standard InChI Key:  ILAQEIPIKWBRQC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5194332

    ---

Associated Targets(non-human)

PMII Plasmepsin 2 (774 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 587.72Molecular Weight (Monoisotopic): 587.2784AlogP: 7.66#Rotatable Bonds: 10
Polar Surface Area: 107.44Molecular Species: ACIDHBA: 6HBD: 2
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.22CX Basic pKa: 3.57CX LogP: 7.71CX LogD: 5.04
Aromatic Rings: 5Heavy Atoms: 44QED Weighted: 0.16Np Likeness Score: 0.04

References

1. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source